Notice of Proposed Sale · 144
SOPHiA GENETICS SA
SOPHNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- SOPHIA GENETICS SA
- Issuer CIK
- 0001840706
- SEC file number
- 001-40627
- Phone
- 41216941060
- Person for whose account securities are to be sold
- KATHY L HIBBS
- Relationships to issuer
- Director
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 18,750 | 158,437.50 | 85,127,825 | 08/25/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 06/18/2025 | Restricted Stock Units | Issuer | 18,750 | N | 06/18/2025 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/25/2026
- Signed
- /s/ Kathy L Hibbs
- Plan adoption dates
- 12/01/2025
Company context
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.